Anti-epileptic Drugs Market, by Generation (First Generation, Second Generation, and Third Generation), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Reg

Anti-epileptic Drugs Market, by Generation (First Generation, Second Generation, and Third Generation), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Epilepsy is a chronic disorder that affects the brain and causes frequent seizures. Seizures are bursts of electrical activity in the brain that temporarily affects its functioning. Epilepsy can start at any age, but usually starts either in childhood or in people over the age of 60. There are several tests conducted to determine the activity in the brain. An electroencephalogram (EEG) is conducted on epilepsy patients to check for unusual electrical activities in the brain. A brain scan is also used to spot problems in the brain that is sometimes caused due to epilepsy such as an unusual growth (brain tumour), damage to the brain, and scarring in the brain. Magnetic resonance imaging (MRI) scan is also used to conduct the brain scan in patients suffering from epilepsy. It uses magnetic fields and radio waves to create an image of the brain. Anti-epileptic drugs are also used in the treatment of epilepsy, which are categorized into three generations.
Market Dynamics
Increasing number of product launches is expected to drive the global anti-epileptic drug market. For instance, in January 2016, Mylan N.V. launched Felbamate tablets USP in 400 mg and 600 mg dosages. Felbamate tablets are the generic version of Felbatol tablets used for the treatment of epilepsy. These are recommended for the treatment of partial seizures, with or without secondary generalizations in adults with epilepsy and in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.
However, growth of the global anti-epileptic drug market is expected to be hampered over the forecast period, owing to potential side effects of the anti-epileptic drugs. For instance, according to the Journal of Family Practice, the side effects of anti-epileptic drugs include, the medication Phenytoin, which is used for treating epilepsy patients causes a pattern of defects collectively called the Fetal Hydantoin Syndrome (FHS), which is characterized by variable degrees of hypoplasia and ossification of the distal phalanges and craniofacial abnormalities.
Key features of the study:
This report provides in-depth analysis of the global anti-epileptic drug market size (US$ in Mn), and compound annual growth rate (CAGR) for the forecast period (2022 - 2028), considering 2021 as the base year.
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players.
It profiles key players in the global anti-epileptic drug market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study are Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Zogenix, Dr. Reddy’s Laboratories Ltd., Alkem Labs, SK Biopharmaceuticals, Eisai Co., Ltd., Angelini S.p.a., Sun Pharmaceutical Industries Ltd., UCB S.A, Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Bausch Health Companies Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics.
The global anti-epileptic drug market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for drug market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global Anti-epileptic Drugs Market, By Generation:
First Generation
Second Generation
Third Generation
Global Anti-epileptic Drugs Market, By Route of Administration:
Oral
Intravenous
Global Anti-epileptic Drugs Market, By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Global Anti-epileptic Drugs Market, By Region:
North America
By Country:
U.S.
Canada
By Generation:
First Generation
Second Generation
Third Generation
By Route of Administration:
Oral
Intravenous
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Generation:
First Generation
Second Generation
Third Generation
By Route of Administration:
Oral
Intravenous
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Generation:
First Generation
Second Generation
Third Generation
By Route of Administration:
Oral
Intravenous
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Generation:
First Generation
Second Generation
Third Generation
By Route of Administration:
Oral
Intravenous
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Generation:
First Generation
Second Generation
Third Generation
By Route of Administration:
Oral
Intravenous
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Generation:
First Generation
Second Generation
Third Generation
By Route of Administration:
Oral
Intravenous
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Novartis AG
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
GlaxoSmithKline Plc.
Johnson & Johnson Service, Inc.
Teva Pharmaceutical Industries Ltd.
Pfizer, Inc.
Zogenix
Dr. Reddy's Laboratories Ltd.
Alkem Labs
SK Biopharmaceuticals
Eisai Co., Ltd.
Angelini S.p.a
Sun Pharmaceutical Industries Ltd.
UCB S.A
Sanofi S.A.
Sumitomo Dainippon Pharma Co., Ltd.
Bausch Health Companies Inc.
“*” marked represents similar segmentation in other categories in the respective section.